← Leaderboards
David L. Williams
East Tennessee State University
$8,988,272
Attributed
$13,174,778
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,174,778 · 7
By mechanism
R01$11,795,141 · 3
R21$1,379,637 · 4
Top collaborators
- Chuanfu Li13 shared
- Edward R Sherwood10 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventSeptic ShockMolecularResponseCritical IllnessSepsisInflammatory ResponseInfectionSepsis SyndromeComplexSepticMorbidity - Disease RateMacrophagePhenotypeSignal TransductionMultiple Organ FailureOrganGrantFunctional DisorderUnited StatesAdult Respiratory Distress SyndromeEventEffective TherapyNatural Immunity
Grant awards (43)
Glucan glycomimetics: A new approach to stimulating innate immune training$226,500
R21 · FY2025 · AI · contact PI
Training Innate Immunity: A new approach to the treatment of Sepsis$526,721
R01 · FY2024 · GM · contact PI
Glucan glycomimetics: A new approach to stimulating innate immune training$188,750
R21 · FY2024 · AI · contact PI
Development of an alpha-1 phosphate mannan vaccine against the emerging fungal pathogen Candida auris.$187,500
R21 · FY2024 · AI · contact PI
Training Innate Immunity: A new approach to the treatment of Sepsis$526,721
R01 · FY2023 · GM · contact PI
Development of an alpha-1 phosphate mannan vaccine against the emerging fungal pathogen Candida auris.$225,000
R21 · FY2023 · AI · contact PI
Equipment supplement to "Training Innate Immunity: A new approach to the treatment of sepsis"$136,305
R01 · FY2023 · GM · contact PI
Training Innate Immunity: A new approach to the treatment of Sepsis$528,401
R01 · FY2022 · GM · contact PI
Training Innate Immunity: A new approach to the treatment of Sepsis$553,544
R01 · FY2021 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$333,000
R01 · FY2021 · GM
Innate Immunity and Cardiovascular Function in Sepsis$333,000
R01 · FY2020 · GM
Training innate immunity: A new approach to the treatment of sepsis$534,819
R01 · FY2019 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$333,000
R01 · FY2019 · GM
Training innate immunity: A new approach to the treatment of sepsis$541,266
R01 · FY2018 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$279,315
R01 · FY2018 · GM
Training innate immunity: A new approach to the treatment of sepsis$549,730
R01 · FY2017 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$306,600
R01 · FY2017 · GM
Training innate immunity: A new approach to the treatment of sepsis$567,590
R01 · FY2016 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$306,600
R01 · FY2016 · GM
Equipment Supplement request for a BD LSR Fortessa Flow Cytometer$127,430
R01 · FY2016 · GM · contact PI
Innate Immunity and Cardiovascular Function in Sepsis$306,600
R01 · FY2015 · GM
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2015 · GM · contact PI
Equipment Supplement request for an Octet RED96 biolayer interferometry instrument$89,525
R01 · FY2015 · GM
Innate Immunity and Cardiovascular Function in Sepsis$306,600
R01 · FY2014 · GM
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2014 · GM · contact PI
Amelioration of Sepsis by Macrophage Activation$277,029
R01 · FY2013 · GM · contact PI
Innate immunity and cardiovascular function in sepsis$294,324
R01 · FY2012 · GM
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2012 · GM · contact PI
Innate immunity and cardiovascular function in sepsis$294,324
R01 · FY2011 · GM
Innate immunity and cardiovascular function in sepsis$297,297
R01 · FY2010 · GM
Innate immunity and cardiovascular function in sepsis$300,300
R01 · FY2009 · GM
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2009 · GM · contact PI
Amelioration of Sepsis by Macrophage Activation$114,990
R01 · FY2009 · GM · contact PI
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2008 · GM · contact PI
Amelioration of Sepsis by Macrophage Activation$287,077
R01 · FY2007 · GM · contact PI
Amelioration of Sepsis by Macrophage Activation$295,650
R01 · FY2006 · GM · contact PI
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION$253,865
R01 · FY2004 · GM
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION$253,865
R01 · FY2003 · GM
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION$253,865
R01 · FY2002 · GM
Dietary supplementation with glucan enhances immune fn$155,634
R21 · FY2002 · AT
AMELIORATION OF SEPSIS BY MACROPHAGE ACTIVATION$250,403
R01 · FY2001 · GM
IMMUNE RECOGNITION OF CANDIDA--ROLE OF CELL WALL$241,556
R21 · FY2001 · AI
Dietary supplementation with glucan enhances immune fn$154,697
R21 · FY2001 · AT